Y-mabs and takeda announces marketing authorization in israel for danyelza® (naxitamab-gqgk) for neuroblastoma

New york and petah tikva, israel, aug. 30, 2022 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer and takeda israel, a wholly owned subsidiary of takeda pharmaceutical company limited (tse:4502/nsy:tak) ("takeda"), announced today that the israeli ministry of health has approved danyelza in israel for the treatment, in combination with granulocyte-macrophage colony-stimulating factor (“gm-csf”), of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.
YMAB Ratings Summary
YMAB Quant Ranking